(Q45729133)

15 December 2017

title

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies (English)

1 reference

15 December 2017

9

1 reference

15 December 2017

10

1 reference

15 December 2017

E Menu

5

0 references

author name string

M Lemaire

1

1 reference

15 December 2017

M D'Huyvetter

2

1 reference

15 December 2017

T Lahoutte

3

1 reference

15 December 2017

E Van Valckenborgh

4

1 reference

15 December 2017

E De Bruyne

6

1 reference

15 December 2017

P Kronenberger

7

1 reference

15 December 2017

U Wernery

8

1 reference

15 December 2017

K Vanderkerken

11

1 reference

15 December 2017

publication date

9 October 2013

1 reference

15 December 2017

1 reference

15 December 2017

volume

28

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

444-447

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.292

15 December 2017

exact match

0 references

cites work

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Naturally occurring antibodies devoid of light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Nanobodies as novel agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Efficient cancer therapy with a nanobody-based conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Targeted therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.292

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24166214

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24166214

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.292

1 reference

Dimensions Publication ID

15 December 2017

1013006446

0 references

1 reference